These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 30968269)

  • 1. Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment.
    Nayak R; Meerovich I; Dash AK
    AAPS PharmSciTech; 2019 Apr; 20(4):160. PubMed ID: 30968269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
    Shi J; Xiao Z; Kamaly N; Farokhzad OC
    Acc Chem Res; 2011 Oct; 44(10):1123-34. PubMed ID: 21692448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives.
    Rehan F; Zhang M; Fang J; Greish K
    Molecules; 2024 Apr; 29(9):. PubMed ID: 38731563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifunctional nanomedicine platforms for cancer therapy.
    Zhang H
    J Nanosci Nanotechnol; 2012 May; 12(5):4012-8. PubMed ID: 22852341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.
    Linton SS; Sherwood SG; Drews KC; Kester M
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):208-22. PubMed ID: 26153136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calibration-quality cancer nanotherapeutics.
    Perry JL; Kai MP; Reuter KG; Bowerman C; Christopher Luft J; DeSimone JM
    Cancer Treat Res; 2015; 166():275-91. PubMed ID: 25895873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine applied to translational oncology: A future perspective on cancer treatment.
    Bregoli L; Movia D; Gavigan-Imedio JD; Lysaght J; Reynolds J; Prina-Mello A
    Nanomedicine; 2016 Jan; 12(1):81-103. PubMed ID: 26370707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.
    Ragelle H; Danhier F; Préat V; Langer R; Anderson DG
    Expert Opin Drug Deliv; 2017 Jul; 14(7):851-864. PubMed ID: 27730820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH-sensitive nano-systems for drug delivery in cancer therapy.
    Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
    Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers.
    Raza F; Zafar H; You X; Khan A; Wu J; Ge L
    J Mater Chem B; 2019 Dec; 7(48):7639-7655. PubMed ID: 31746934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivering the power of nanomedicine to patients today.
    Germain M; Caputo F; Metcalfe S; Tosi G; Spring K; Åslund AKO; Pottier A; Schiffelers R; Ceccaldi A; Schmid R
    J Control Release; 2020 Oct; 326():164-171. PubMed ID: 32681950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.
    Tyagi P; Subramony JA
    J Control Release; 2018 Feb; 272():159-168. PubMed ID: 29355619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications.
    Durymanov M; Kamaletdinova T; Lehmann SE; Reineke J
    J Control Release; 2017 Sep; 261():10-22. PubMed ID: 28625673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine for prostate cancer using nanoemulsion: A review.
    Sasikumar A; Kamalasanan K
    J Control Release; 2017 Aug; 260():111-123. PubMed ID: 28583444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine in the Diagnosis and Treatment of Atherosclerosis-A Systematic Review.
    Vaidyanathan K; Gopalakrishnan S
    Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):119-131. PubMed ID: 28925905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization.
    Hua S; de Matos MBC; Metselaar JM; Storm G
    Front Pharmacol; 2018; 9():790. PubMed ID: 30065653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.